GenomeKeyDx

About GenomeKey

GenomeKey, founded in 2018, is a private, pre-revenue diagnostics company tackling the global sepsis and antimicrobial resistance crises. Its core technology is an IVD device that leverages DNA sequencing and machine learning to detect, identify, and provide a full AMR profile for pathogens directly from blood samples in just hours. The company has secured non-dilutive grant funding, notably from CARB-X, and has formed a key collaboration with Oxford Nanopore Technologies to develop its platform. GenomeKey is in the development and validation stage, building towards clinical demonstrations and regulatory approval for its transformative diagnostic system.

Therapeutic Areas